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Abstract
Background: Poorly controlled hypertension (HTN) remains one of the most significant public health problems in
the United States, in terms of morbidity, mortality, and economic burden. Despite compelling evidence supporting
the beneficial effects of therapeutic lifestyle changes (TLC) for blood pressure (BP) reduction, the effectiveness of
these approaches in primary care practices remains untested, especially among African Americans, who share a
disproportionately greater burden of HTN-related outcomes.
Methods/Design: This randomized controlled trial tests the effectiveness of a practice-based comprehensive
therapeutic lifestyle intervention, delivered through group-based counseling and motivational interviewing (MINT-
TLC) versus Usual Care (UC) in 200 low-income, African Americans with uncontrolled hypertension. MINT-TLC is
designed to help patients make appropriate lifestyle changes and develop skills to maintain these changes long-
term. Patients in the MINT-TLC group attend 10 weekly group classes focused on healthy lifestyle changes
(intensive phase); followed by 3 monthly individual motivational interviewing (MINT) sessions (maintenance phase).
The intervention is delivered by trained research personnel with appropriate treatment fidelity procedures. Patients
in the UC condition receive a single individual counseling session on healthy lifestyle changes and print versions of
the intervention materials. The primary outcome is within-patient change in both systolic and diastolic BP from
baseline to 6 months. In addition to BP control at 6 months, other secondary outcomes include changes in the
following lifestyle behaviors from baseline to 6 months: a) physical activity, b) weight loss, c) number of daily
servings of fruits and vegetables and d) 24-hour urinary sodium excretion.
Discussion: This vanguard trial will provide information on how to refine MINT-TLC and integrate it into a standard
treatment protocol for hypertensive African Americans as a result of the data obtained; thus maximizing the
likelihood of its translation into clinical practice.
Trial Registration: Clinicaltrials.gov NCT01070056
Keywords: Hypertension, African American, Therapeutic Lifestyle Changes, Practice-based trial
Background
The disproportionately high prevalence of hypertension
(HTN) and cardiovascular disease mortality in African
Americans is well documented [1]. The age-adjusted
prevalence estimate of HTN in African Americans is
31.8%, compared to 23.3% for whites [2], making Afri-
can Americans the most highly afflicted group in the
United States [3]. Hypertension is the single most com-
mon explanation for mortality disparities between Afri-
can Americans and whites [4]. Fortunately, there is
evidence that increased blood pressure (BP) control pro-
duces cardiovascular benefits in both African Americans
and other ethnic groups [5].
B a r r i e r st h a th i n d e ra d e q u a t eB Pc o n t r o le x i s ta tt h e
individual level, especially in minority populations [6-8].
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adverse lifestyle behaviors such as lack of physical activ-
ity, high sodium intake, poor intake of fruits and vegeta-
bles, and obesity. Several studies have confirmed the
negative association between adverse lifestyle behaviors
and blood pressure [9-14]. The efficacy of lifestyle inter-
ventions in the prevention and treatment of HTN is
well proven [12-20]. Well-studied lifestyle approaches
include weight loss;[21-23] restriction of sodium intake;
[9,15,17,20,24,25] a diet rich in low-fat dairy and, fruits
and vegetables;[18,25,26] limited alcohol intake;[27,28]
and regular exercise [23,29-31]. For example, SBP/DBP
reductions of 5.5/3.0 mm hg (comparable to those
observed in drug trials) were achieved in the Dietary
Approaches to Stop Hypertension (DASH) study, where
patients were randomized to receive a diet rich in fruits
and vegetables and higher in low-fat dairy products ver-
sus a standard diet [18]. The BP reduction was particu-
larly high in African Americans in the DASH trial. A
later lifestyle trial, PREMIER, showed that lifestyle
changes were more effective in BP reduction than advice
only [16]. Further analysis of PREMIER data indicated
that BP reductions were similar or higher among Afri-
can-American patients compared to whites;[32] and
these intervention effects were maintained 18 months
post-intervention [19]. Other trials such as the Trials of
Mild Hypertension Study, Hypertension Control Pro-
gram, Trial Of Nonpharmacologic interventions in the
Elderly (TONE), Trials of Hypertension Prevention-
Phase II, Diet, Exercise and Weight Loss Intervention
Trial and the Primary Prevention of Hypertension have
all reported similar beneficial effects of lifestyle changes
on BP reduction [12,13,15,17,19,33-36]. Based on this
evidence, non-pharmacologic approaches to BP control
have been adopted as standard treatment in hyperten-
sive patients by the Joint National Committee on Detec-
tion, Evaluation and Treatment of Hypertension (JNC)-
5, JNC-6, and JNC-7 treatment guidelines [5,37,38].
However, all of these studies were conducted in clinical
settings, under controlled conditions. If these interven-
tions cannot find a place in clinical practice settings,
their impact on public health will be negligible. This is
particularly true for African Americans, given their
poorer BP control compared to other racial/ethnic
groups,[39] as well as their low participation rates in
these trials. The current study represents an advance in
the non-pharmacologic treatment of HTN in high risk
populations because it emphasizes the translation of an
empirically-validated TLC intervention into clinical
practice.
Study Aims
The primary aim of the Therapeutic Lifestyle Changes
in Clinic (TLC-Clinic) trial is to test the effectiveness of
a practice-based comprehensive therapeutic lifestyle
intervention, delivered through group-based counseling
and motivational interviewing (MINT-TLC) versus a
Usual Care control condition (UC) in reducing BP,
among 200 low-income, poorly controlled hypertensive
African-American patients. The secondary aims are to
evaluate the effect of MINT-TLC versus UC, on changes
in the following lifestyle behaviors from baseline to 6
months: a) physical activity, b) weight loss, c) number of
daily servings of fruits and vegetables and d) 24-hour
urinary sodium excretion. In addition, a secondary aim
will evaluate the effect of MINT-TLC versus UC on BP
control at 6 months.
We hypothesize that patients randomized to the inter-
vention condition (MINT-TLC) compared to those ran-
domized to the UC condition, will exhibit a greater
reduction in systolic BP (SBP) and diastolic BP (DBP) at
6 months; greater levels of physical activity; greater per-
cent change in weight; increased intake of fruits and
vegetables; reduced 24-hour urinary sodium excretion;
and a higher proportion of patients will have adequate
BP control at 6 months. This study is one of few trials
to test the effectiveness of this approach among minor-
ity populations who receive care in primary care
practices.
Methods/Design
Study Design
TLC-Clinic is a randomized controlled trial (RCT) with
two conditions: Intervention condition (MINT-TLC)
and Usual Care condition (UC). Approximately 200
African-American patients with uncontrolled HTN will
be randomly assigned to either the MINT-TLC or UC
conditions. The MINT-TLC intervention is based on
established clinical practice guidelines for prevention
and treatment of HTN, which recommends weight loss
(if overweight), limiting sodium and alcohol intake, reg-
ular physical activity, and eating a low-fat diet that is
rich in fruit and vegetables. MINT-TLC will be con-
ducted by trained Health Educators. Patients attend 10
weekly group classes (intensive phase) followed by indi-
vidual monthly motivational interviewing (MINT) ses-
sions for 3 months (maintenance phase). Makeup
sessions are built in after sessions 4 and 9 for group
members who missed any of the previous sessions.
Assessments are conducted at baseline (visit 1), 3
months (visit 2), and 6 months (visit 3). Participants
receive $20 at the completion of baseline assessment,
$10 at the 3-month visit, and $20 at the completion 6-
month visit ($50 total) for their time and effort in the
study. All participants also receive free metro cards to
help facilitate transportation to and from the study site
for the individual counseling visit (UC condition) or
group classes (MINT-TLC). The primary and selected
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and all outcomes are assessed at the 6-month follow-up
visit.
Study Sites and Population
This study is being conducted within the Ambulatory
Care Practice of the Bellevue Hospital Center (BHC),
the largest comprehensive diagnostic center within the
New York City Health and Hospitals Corporation.
Approximately 20,000 patients receive treatment
annually at BHC’s adult medicine primary care practice,
with just under 60,000 visits in 2009. To be eligible,
patients must self-identify as black/African American, be
at least 18 years old, currently receive care within the
Ambulatory Care Practice and have had at least two
appointments in the past year, have a diagnosis of HTN
with uncontrolled BP on at least two visits in the past
year (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or SBP ≥
130 mmHg or DBP ≥ 80 mmHg for patients with dia-
betes or chronic kidney disease). In addition, all patients
must have uncontrolled BP at the time of the consent
visit, as measured by WatchBP (Microlife; Golden, CO),
an oscilliometric validated BP monitor [40,41]. Patients
are excluded if they are non-English speaking, partici-
pate in other HTN trials, have an arm circumference >
42 cm, have cognitive impairment based on the Com-
prehensive Assessment and Referral Evaluation Demen-
tia Diagnostic Scale (CARE-DIAG) score ≥ 6f o r
patients age 60 and older,[42,43] are unwilling/unable to
comply with the study protocol (either self-selected or
by indicating that they could not complete all requested
tasks including attending intervention classes if they
were to be randomized to the MINT-TLC group), or
unwilling/unable to provide informed consent. All
patients who agree to take part in the study are asked to
provide informed consent. The study was approved by
the Institutional Review Boards of New York University
and Bellevue Hospital Center. The study is monitored
by a Data Safety Monitoring Board.
Recruitment
Three main approaches are used to recruit patients into
this study. First, potentially eligible patients are identi-
fied through a review of electronic medical records
(EMR) using the ICD-9 billing codes for HTN (401-
401.9). The physicians of eligible patients are notified of
their patients’ potential eligibility, and then asked per-
mission to enroll their patients in this study. After con-
sent is obtained from the physicians, eligible patients are
approached by research assistant’s( R A )a tt h e i rn e x t
clinic appointments for screening, consent and baseline
visit. Second, physicians are asked to identify hyperten-
sive patients in their practices through the use of ICD-9
billing codes. Once a patient is identified who fulfills the
inclusion criteria, the RA calls the patient and invites
him or her to complete the eligibility screen, and if eligi-
ble, to consent and complete the baseline visit. Study
investigators (GO, JR, TO) also conduct in-service visits
at the study sites prior to patient enrollment and every
3 months thereafter to explain the study rationale, its
significance and procedures. At this time, physicians are
given a business card that lists eligibility criteria and
contact information for the RAs. Finally, flyers are hung
in the waiting room of the Ambulatory Care Practice
and RAs approach patients about the study in the wait-
ing areas.
Randomization
After completion of consent procedures and baseline
data collection, a list of patient identification numbers is
sent on a weekly basis to the data management team to
be randomized in a 1:1 ratio to either the MINT-TLC or
UC group. This project has a hierarchical study design
with each patient nested within a primary care physician
and patients are recruited at different times. Randomiza-
tion is within primary care physician. Therefore, a rando-
mization algorithm developed by the Data Coordinating
Center at the Research Division of the Hebrew Home at
Riverdale was used; this algorithm has yielded balanced
groups for numerous studies. This randomization proce-
dure is carried out using a SAS macro after a subject
completes the baseline interview. A random number
from 0 to 1 is used to determine the assignment group.
The standard cut score is set at 0.5 for the first n subjects
from the same provider, 4 for this study. Those who
receive a random number between 0 and 0.5 are assigned
to the control group and those with a random number
greater than 0.5 are assigned to the intervention group.
The balance between the groups within each provider is
weighted carefully after the total number of subjects
from a group reaches a pre-specified number. If more
than the n subjects are randomized initially, the cut score
for the next subject is equal to the ratio of the experi-
mental group (n1) to the subjects already randomized
(m) for that group (n1/m). The cut score is adjusted
according to the previous number of subjects
randomized.
Patients are informed of the results of randomization
by an RA in person or by phone; at this time, the RA
discusses the intervention/counseling session schedule,
and answers any additional questions. Given the nature
of the intervention, it is impossible to blind the RAs to
the assigned condition. However, the dimension that the
RA’s knowledge of the assigned condition could possibly
affect is the BP measurement - the primary outcome of
this study. To reduce the potential for this bias, we use
an automated BP device (WatchBP). Neither the RA nor
the patients see the measurements during this process,
which prevents the RA from influencing the BP
readings.
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MINT-TLC Condition
This intervention is based on established clinical prac-
tice guidelines for prevention and treatment of HTN,
which recommends weight loss (if overweight), regular
physical activity, limiting and/or reducing sodium and
alcohol intake, and eating a low-fat diet that is rich in
fruit and vegetables [5]. Patients attend 10 weekly group
classes over 12 weeks (intensive phase) followed by
monthly, individual telephone-based MINT sessions for
3 months (maintenance phase). Makeup sessions are
built in after session 4 and session 9 for group members
who missed any of the previous sessions. The methodol-
o g y ,s t r u c t u r ea n dt h ec o n t e n to ft h eg r o u pc l a s s e si s
patterned after PREMIER and Healthy Eating and Life-
style Program (HELP) developed by Kumanyika et al.
[44] The HELP program is based on the group counsel-
ing approach used in the Trial Of Nonpharmacologic
interventions in the Elderly (TONE) trial, and was cultu-
rally tailored for African Americans. PREMIER is a com-
prehensive multi-component lifestyle program which
incorporates the DASH dietary pattern [18]. The addi-
tion of three individual MINT sessions to this protocol
was carefully chosen to mimic the structure of the two
major trials that have tested the efficacy of comprehen-
sive TLC in hypertensive patients [18,20]. The metho-
dology, structure and content of the individual MINT
sessions are patterned after our recently completed
study in the same population [45].
Intensive Phase (Group Classes) The group classes are
conducted by Health Educators trained in behavioral
counseling approaches. Each class lasts between 60 and
90 minutes, and is structured so that homework from
previous sessions, a review of the goals participants set
the previous week, feedback and trouble shooting for
skill-building and new content is covered in each ses-
sion. The sessions focus on developing skills, goal-set-
ting and generating strategies for behavior change as
well as support for relapse prevention. Each session fol-
lows a similar structure and includes the following com-
ponents: 1) Overview of HTN and antihypertensive
medications; 2) DASH eating plan 3) Goal setting and
healthy living diaries; 4) Serving sizes, portion control
and food labels (with emphasis on sodium monitoring);
5) Physical activity; 6) Building skills for meal planning
and shopping; 7) Recipe modification and eating away
from the home; 8) Stress Management; 9) Eating trig-
gers and mindful eating; and 10) Planning for lasting
change. The group classes are structured to be very
interactive with patient input and smaller group activ-
ities that foster problem solving, support, and program
ownership. The specific content of classes is shown in
Table 1.
Extended Phase (Monthly Individual MINT Sessions)
The individual telephone-based MINT sessions are con-
ducted by the trained Health Educators. The goal of this
phase is to help patients focus on problem solving, goal
setting, and prevention of relapse with regard to each of
the therapeutic lifestyle changes adopted during the
intensive phase. The sessions focus on individual needs
to tailor intervention strategies to the patient’s personal
context including social support, specific behavior
change goals, problem-solving, and maintaining motiva-
tion during challenging situations. Each session assumes
the following steps: 1) assessing the patient’s motivation
a n dc o n f i d e n c ei ne n g a g i n gi nag i v e nb e h a v i o r-p h y s i -
cal activity, dietary restriction of sodium, increased
intake of fruits and vegetables, stress management or
adherence to prescribed antihypertensive medications; 2)
eliciting barriers and concerns about adoption of each
lifestyle modification; 3) summarizing in a non-threaten-
ing manner the ‘pros’ and ‘cons’ of the patient’sc o n -
cerns, thereby eliciting positive self-motivational
statements about the behavior; 4) providing a menu of
options to the patient based on the nature of barriers
elicited from the patient; 5) assessing each patient’s
values and goals, in order to help the patient link cur-
rent health behavior patterns to core values and life
goals. The session ends with a global summary of what
was discussed and a clarification of an action plan
agreed upon. Each session lasts up to 30 minutes and is
conducted with the aid of a standardized counseling
script [45].
Monitoring treatment fidelity (intensity and the dose
of the intervention) Adherence to the intervention pro-
tocol is an important aspect of this study given its inten-
sity. At the trial’s inception, the Health Educators
participated in a 3-day training that consisted of an
overview of the behavioral framework of the interven-
tion; the curriculum; and basic group facilitation skills
taught through role-playing and didactic instruction. In
addition, the Health Educators participated in a 2-day
training on motivational interviewing skills including an
overview of the basic principles of MINT techniques,
development of problem-solving approaches, and prac-
tice sessions in the form of role-plays. Weekly meetings
with study staff are held to discuss the sessions and plan
for the subsequent week. Booster training sessions are
also conducted monthly to minimize drift in MINT
counseling skills.
All group and individual MINT sessions are audio-
taped and used for two related purposes: (1) to provide
feedback and ongoing training/supervision of the Health
Educators and (2) systematic review for treatment fide-
lity. The relatively immediate review and use of the
recordings serve to facilitate the feedback and coaching
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dual Health Educators, a training approach that has pro-
v e nt ob em o s te f f e c t i v ei np r e v i o u ss t u d i e so fM I N T
[46]. Audio files are also archived to allow for systematic
sampling of 30% of the MINT sessions, which will be
coded in order to assess adherence to MINT principles
using the Motivational Interviewing Treatment Integrity
(MITI) scale [47]. The MITI scoring system was recently
validated in an addiction treatment setting and found to
have satisfactory inter-rater reliability and good conver-
gent and discriminative validity [47]. In addition, this
session archive will be used for future process evaluation
to identify the important components of MINT used in
the health behavior setting, as suggested by other
researchers [48]. Finally, we record completion of the
food diary and homework assignments as well as atten-
dance of group classes and note the compliance and
attrition rates.
Description of the Control Condition/Usual Care
Patients randomized to the UC condition receive stan-
dard HTN treatment recommendations as determined by
their physicians. In addition, they receive a 30-minute
individual counseling session on therapeutic lifestyle
modification, similar to PREMIER [16]. To match the
MINT-TLC group for content of intervention material,
those in the UC group also receive print versions of the
intervention curriculum that is distributed in the group
classes.
Outcomes assessments
The primary outcome is change in SBP and DBP at 6
months. Secondary outcomes include: intake of fruits
and vegetables; level of physical activity; percent change
in weight; level of 24-hour urine sodium excretion; and
proportion of patients with adequate BP control at 6
months. Study assessments for primary outcomes are
completed at the baseline visit, 3 and 6 months; data
collection intervals are given in Table 2. All assessments
are performed by trained RAs and divided into three
categories: (1) physiological and anthropometric mea-
sures, (2) self-report measures and (3) chart data. Table
2 summarizes the measures according to their timeline.
Primary Outcome
Blood Pressure
At baseline, 3 blood pressure (BP) readings are taken by a
trained RA using an automated BP monitor (WatchBP
Office Device; Microlife; Golden, CO) with the patient
seated comfortably for 5 minutes before measurement, fol-
lowing AHA guidelines [49]. The average of the 3 readings
is used as the measurement for each visit. Uncontrolled
BP is defined as an average SBP ≥ 140 mm Hg or DBP ≥
90 mm Hg. The criteria for those with co-morbid diabetes
Table 1 Major Content of TLC Intervention Sessions
Session Content
1. Getting Started & Blood Pressure
Overview
Introduction to the program. Education about blood pressure and hypertension. Discussion of risk factors
for hypertension and behavioral approached to controlling hypertension.
2. Medications Introduction to medications for HTN. Myths and Facts about HTN medications, tips for taking charge of
medications, and understanding medication labels. Discussion of current medication taking behavior and
goals for adherence. Introduction to the Medication Diary. At-Home Activity: Medication Diary.
3. DASH Eating Plan & Introduction to
Goal Setting
Introduction to the DASH Eating plan. Discussion of DASH pyramid, food groups and servings. SMART
goal setting for healthy eating goal. Introduction to Healthy Living Diary (food and activity diary). At-
Home Activity: Healthy living diary, Medication diary.
4. Food Labels & Sodium Discussion about reading food labels and nutrition facts. Facts about salt and sodium, and tips for how
to lead a low sodium life. Revisiting healthy eating goal and introduction of rewards. At-Home Activity:
Healthy living diary, Medication diary.
5. Physical Activity & Stress
Management
Introduction to physical activity. Discussion of FITT guidelines, impact of exercise on HTN, finding time
for physical activity. Physical activity goal setting. Discussion of stress and health. Quiet time activity. At-
Home Activity: Healthy living diary, Medication diary.
6. Serving Sizes and Portion Control Review of medications and DASH eating plan. Discussion about serving sizes, portion control and the
plate method. Revisiting the physical activity goal. At-Home Activity: Healthy living diary, Medication
diary.
7. Meal Planning & Shopping Discussion of the buddy system and physical activity. Discussion of planning for meals and tips for
shopping. Checking in on goal progress. At-Home Activity: Healthy living diary, Medication diary.
8. Eating Triggers & Eating Awareness Discussion of eating triggers and eating awareness. Mindful eating activity. Revisit health eating goal. At-
Home Activity: Healthy living diary, Medication diary.
9. Specials Occasions, Eating Out
&Recipe Substitutions
Discussion of strategies for attending special occasions and eating out. Recipe substitutions. Revisit
physical activity goal. At-Home Activity: Healthy living diary, Medication diary.
10. Planning for Lasting Change Review of overall program content. Discussion of what worked with medication adherence. Adopting
the attitude “It’s not a diet it’s a lifestyle.” Discussion of physical activity throughout the year. Planning
for lasting change activity.
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Hg.
Secondary Outcomes
Dietary intake of fruits and vegetables is assessed via a
web-based graphical food frequency questionnaire
(FFQ), which was adapted from the FFQ developed by
Fred Hutchinson Cancer Research Center [50]. The
instrument assesses how oft e n ,a n di nw h a ta m o u n t
patients eat a list of over 125 food items. The Graphical
FFQ assesses portion size using photographs in order to
get accurate responses.
Physical activity is assessed via a computerized version
of the International Physical Activity Questionnaire
(Long IPAQ) [51]. The Long IPAQ is a 32-item measure
that allows for evaluating the amount of health-related
vigorous and moderate-intensity physical activity as well
as sedentary behaviors and physical activity limitations
in adults over seven days. The number of hours and
minutes per day participants report spending in various
types of physical activity is multiplied by the average
metabolic equivalent (METs) of each category and
summed to calculate energy expenditure as kcal/kg/min-
utes/week.
Height and weight is measured without shoes and with
lightweight clothes using a stadiometer and a validated
digital scale (WB-800S Digital Medical Weight Scale;
Tanita Corporation of America, Inc.; Arlington Heights,
Illinois), respectively. All measurements are recorded to
the nearest 0.1 cm and 0.1 kg. These data are used to cal-
culate and determine the patient’sb o d ym a s si n d e x
(BMI). The difference in weight from baseline to 6
months serves as a measure of weight loss. Height is only
measured at the baseline visit while weight is measured
at baseline and 6 months.
A 24-hour urine sample is collected at baseline and 6
months for analysis of urinary sodium excretion.
Trained RAs provide instructions and a collection con-
tainer in the clinic. Patients are also provided with a col-
lection log on which they record the start and stop time;
any missed voids, spills, and any other problems with
the collection. Patients with inadequate collections (e.g.,
< 20 hours or < 500cc or > 24 hours) are asked to
repeat the process.
BP control is defined as an average BP (based on 3
readings with automated BP monitor) that fulfills the
JNC-7 criteria of SBP < 130 and DBP < 80 mmHg
(patients with diabetes or chronic kidney disease); or SBP
< 140 and DBP < 90 mmHg (for all other patients).
Chart Extraction Data
All patients have their medical records reviewed at base-
line and at 6-months by study staff. Chart data extraction
includes duration of HTN, evidence of target organ
damage, changes in prescribed antihypertensive medica-
tions dosages (this reflects the intensity of treatment).
Others include frequency of clinic visits and reasons for
visits; and use of other medications that are known to
affect BP such as NSAIDS and hormone replacement
therapy. Patients in this population have comorbid ill-
nesses, which may affect BP levels - the primary outcome
of this study. As such, we will use the Charlson Comor-
bidity Index (CCI)[52] to adjust for both the confounding
effects of comorbidity on BP and their non-uniform
prognostic impact on patients. The CCI is a weighted
index for prospectively classifying comorbid conditions,
which takes into account the number and seriousness of
comorbid diseases.
Data on patient socio-demographic characteristics are
also collected for description of the cohort and to
Table 2 Study measures by modality
MEASURES Baseline 3 Months 6 Months
PHYSIOLOGICAL
Office BP Measurements X X X
24-hour ABPM X X
Height, Weight, and Body Mass Index X X
Blood and Urine Specimen X X
SELF-REPORT
Patient Demographics X X
Cognitive Screen for participants ≥ 60 yrs (CARE-DIAG) X
Diet (Food Frequency questionnaire) X X X
Physical Activity (IPAQ Long Version) X X X
CHART DATA
Frequency of Clinic Visits and Medication Changes X X
Hypertension characteristics X X
Medical Comorbidity (Charlson Comorbidity Index) X X
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include age, gender, education level, income, marital sta-
tus, employment status, and health insurance status.
Analysis
Sample Size and Power Analysis
T h es a m p l es i z ei sb a s e do nt h en u m b e ro fp a t i e n t s
required to provide adequate power to test the primary
hypothesis of group differences in SBP and DBP. The
power calculations assumed separate analyses of SBP and
DBP; however, the use of multivariate analyses of var-
iance (MANOVA) to examine the primary outcomes
simultaneously, assuming that they are correlated was
also considered. Power is expected to be greater with the
use of MANOVA. However, we will use Full Information
Maximum Likelihood estimation procedures for the pri-
mary analyses, thereby allowing us to include participants
who do not complete the follow-up assessment in the
analysis (on an intent-to-treat basis). The original power
calculations were conservatively based on the number of
participants who were anticipated to complete the fol-
low-up assessment.
Based on our own clinical experience and estimates
from other clinical trials in uncontrolled hypertensive
patients,[16-18,20,53-57] we estimate that the cross-sec-
tional standard deviations (SD) of SBP and DBP at base-
line will be about 15/12 mm Hg. It was assumed that the
SD at follow-up will be as much as 25% larger in the
MINT-TLC group, and that the correlation between
baseline and follow-up BPs will be 0.6 in the UC group
and 0.4 in the MINT-TLC group (possibly as a result of
heterogeneity of treatment response). Design effects of
patients clustered within physicians has been found to be
minimal in our experience; for example the intracluster
correlation coefficient (ICC) was estimated to be 0.02 or
less, and cluster sizes are relatively small. Clustering
results in reduction in power and increased requirements
for sample size. The variance inflation factor (VIF) used
in power calculations involving clustering depends on the
size of the cluster (number of patients treated by each
physician) and ICC. Power calculations were examined in
sensitivity analyses (not shown), assuming that heteroge-
neous variances may require modeling. The original
power calculations were updated using actual data from
the beginning of the trial. It was found that the average
cluster size was 1.55 (SD = 1.39, ranging from 1 to 10
clusters and the total number of physicians was 92). The
following assumptions were used in the power calcula-
tions: s (population standard deviation) = 15 for SBP and
12 for DBP; a = 0.05, two-tailed; R = 0.9 (reliability); g =
2 (groups); n = 3 (waves, t = 0, 3 and 6 month); s2
x(var-
iance of time) = 0.125; inflation factor (IF) = 1+(cluster-
size-1)*ICC with clustersize = 1.55 and ICC = 0.01.
Thus, 100 subjects per group will provide 80% power
to detect a 6 to 7 mm Hg differential change in SBP
and a 5 to 6 mm Hg differential change in DBP, based
on testing the Time (pre through post-intervention
waves) × Group interaction in a mixed model, allowing
for heterogeneous variances, serial correlations and
modeling of design effects. As described below, analyses
will be performed under an intent-to-treat design; there-
fore all patients, including those who drop out of the
study will be invited back for the final assessments.
Analysis of the Primary Aim
The primary pre-planned analyses are to examine SBP
and DBP separately; however, if the two variables are
correlated, MANOVA will be used to test the hypothesis
that those assigned to MINT-TLC will, on average, exhi-
bit greater 6-month decreases in SBP and DBP than
those assigned to the UC condition. A mixed (fixed and
random) effects model using SAS Proc Mixed is the
method planned for use. Such models permit modeling
heterogeneous group variances and serial correlations
over time as well as the design effects of clustering.
Moreover, the use of the missing data algorithms within
the mixed procedure permits the inclusion of all indivi-
duals with at least one wave of data. The primary test
concerns the Group × Time interaction, and the result-
ing F-test will provide the primary “intent-to-treat” test
of the hypothesis. If this is statistically significant at the
two-tailed a = 0.05 level, the magnitude of the treat-
ment effect will be estimated with 95% Confidence
Interval (CI), separately for SBP and DBP. The expecta-
tion is that the randomization of patients to treatment
arm and the absence of significant selection and/or attri-
tion biases will obviate the need for any covariates in
the analysis. This has been the normative experience of
the data coordinating center in over 100 randomized
trials. However, in the unlikely event that imbalances
are identified, propensity score analyses or other meth-
ods will be used to condition on the covariates. The pre-
dicted values of those analyses will be included as
covariates together with the group by covariate interac-
tions in the model. This procedure is most often applied
in quasi-experimental and observational studies.
Discussion
Study Implementation: Challenges and Lessons Learned
In the first few months of implementing the study, we
encountered several “real world barriers” that have made
us reevaluate the suitability of the TLC-Clinic protocol as
originally conceived. Several of the challenges faced by the
TLC-Clinic trial relate to the difficulties involved in trans-
lating an empirically-validated therapeutic lifestyle inter-
vention into clinical practice. Moving away from a tightly
controlled academic research center to a practice-based
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contend with the need to uphold the methodological rigor
of a randomized clinical trial while maintaining the flex-
ibility to work within a busy primary care practice.
To maintain this balance, the investigative team holds
biweekly strategic meetings where barriers and solutions
are discussed within the context of the study’sa i m s .
Moreover, we adopted several successful strategies based
upon our experiences with implementation of similar
procedures from previous clinical trials in practice-based
settings [55,56]. As a result, we have had little difficulty
in delivering the intervention at the Ambulatory Care
Practice and this success can be attributed to the follow-
ing factors; first, the presentation of the study to the
clinic director, primary care providers and allied health
workers in the practice on multiple occasions during
staff meetings in order to gain the buy-in from providers
and clinic staff. Second, we had one of the primary care
providers to serve as co-investigator on the study as a
physician champion for the study within the practice.
Third, we engaged the medical assistants in recruitment
of patients and we arranged for a dedicated space to
deliver the interventions to the patients by asking the
director to provide available space within the practice.
The two main barriers to date are patient recruitment
and the poor attendance rates of the group sessions and
the low participation rates for the telephone-based MI
counseling sessions. Below, we summarize the strategies
we have employed to address these challenges as
resource for other researchers who are interested in
translating efficacious lifestyle interventions into commu-
nity-based practices.
Recruitment Challenges
One of the most frequently encountered barriers to
recruitment in a primary care clinic is the limited avail-
ability of private space to conduct patient screenings,
consent, and assessments. Due to a high patient caseload,
exam rooms are often in use, making it difficult for RAs
to secure a private space to meet with study participants.
As a result, RAs are often faced with the task of juggling
space and time constraints so as not to interfere with the
clinic workflow or compromise patient rapport. The RAs
have been flexible and quick to adapt to such situations
to ensure that patients are comfortable and that the
interviews remain confidential while not interfering with
their medical visits. We have also developed a rapport
with clinic staff that assist in identifying empty exam
rooms, when available.
A second recruitment challenge that is more likely to be
encountered when recruiting from a community clinic is
related to the inclusion criteria chosen to select the study
population. It quickly became apparent that the original
criterion that was contingent on patients receiving care
within the NYU Ambulatory Care Network for at least
one year restricted the pool of eligible patients substan-
tially, resulting in recruitment numbers below the target
goal. In response, the inclusion criterion was changed to
“currently receiving primary care within the NYU Ambu-
latory Care Network and has had at least two primary care
appointments in the past year” and “at least one high BP
reading in the past year” which resulted in a significant
increase in patients meeting the initial eligibility criteria.
Several other changes have been made to the eligibility cri-
teria to boost recruitment including reevaluating patients
with BP that was too high at the initial screening and
including patients with a history of substance abuse if the
patients’ provider agrees they would be a good candidate.
The methods of identifying eligible patients for the
study also presented several challenges. Based on pre-
vious experience,[55] we planned to capitalize on the
clinic’s EMR system to prescreen potentially eligible par-
ticipants based on the study inclusion criteria. During
the initial months of the trial implementation, a list of
eligible patients was created each week indicating
patient’s appointment time and physician name. Despite
having this information, the number of potential partici-
pants recruited from this list was extremely low and is
no longer used as a recruitment strategy for three key
reasons. First, the EMR system is not equipped to con-
duct a refined search strategy and so, a significant
amount of staff time was needed to cross check the
information on the list with individual medical records
to determine initial eligibility. Second, a high percentage
of patients on the refined list broke their scheduled
appointment. To address the latter issue, we created an
‘opt-out letter’ whereby patients who did not show up
for their appointment were mailed a letter, signed by
his/her physician, two weeks before the patient’sn e x t
appointment. However, this too produced a low yield
and is no longer used as a recruitment strategy. Third,
physicians often see patients back-to-back throughout
the day (average of 9 patients per session, of which 1 is
a new patient) and do not have the time to speak with
the RAs about potentially eligible study participants. In
addition, due to the inherent nature of the time-con-
strained visit as well as competing medical priorities,
physicians are often unable to directly encourage
patients to enroll in the study. However, without the
support from their primary care physicians, some
patients are less inclined to learn more about the study.
To date, “cold recruiting” patients in the waiting room
has proven to be the most effective recruitment strategy.
However, while numerous patients in the waiting area
express initial interest in the TLC program, many do
not meet the initial screening criteria due to active
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being a BHC primary care patient, missing BP data or
no HTN diagnosis in the EMR, and limited English pro-
ficiency, with a majority of African patients speaking
French Creole as their primary language. Many others
cannot commit to attending classes at BHC on a weekly
basis because they work full time or live in the outer
boroughs and cannot afford to travel to Manhattan on a
regular basis. For those patients who do meet initial cri-
teria, the RA typically schedules a meeting at a later
date to complete the consent and initial study visit.
However, many patients are reluctant to come back to
the clinic a second day and express disappointment that
car fare is not provided for attending any of the study-
related visits. Despite the many recruitment challenges
we have encountered, approximately 60% of patients
have been approached and cold-recruited in the clinic
waiting rooms. The successful use of cold recruitment
attests to the RAs ability to develop a trusting interper-
sonal relationship with patients, which is also reflected
in the 83% retention rates for the 3 and 6-month fol-
low-up visits.
Mode of Intervention Delivery
The potential for low patient participation rates in the
group classes and MINT counseling sessions is another
real-world challenge encountered in this study. We have
adopted several strategies to facilitate high participation
rates, including offering classes in the clinic; determining
a cohort’s class schedule based on the most frequently
selected time and date chosen by patients during the elig-
ibility screen visit; and offering Saturday classes and
make-up classes on an alternate day and time. Despite
these efforts, approximately 50% of patients attend the
weekly group classes, of which 35% have attended 9 to 10
of the classes (total of 10 classes). Most frequent reasons
for low group class attendance include patients’ reporting
another time commitment or conflict, being too ill to tra-
vel to the classes on a weekly basis, inability to reach the
patient to remind them of the class time and location,
and patient’s having difficulty arranging for paratransit
services (e.g., Access-a-Ride) to bring them to the clinic
on off hours (evenings and weekends).
Similarly, approximately 50% of patients have received
the telephone-based MINT sessions to date. To increase
the completion rate, Health Educators make four call
attempts to each patient at different times of the day over
a 2-week period before they are considered a missed
appointment. However, it is often difficult to reach
patients by phone as many participants have intermittent
use of their phones and their numbers change frequently.
Letters signed by the Health Educators are also sent to
patients with the study coordinator’s phone number. It is
noteworthy that 47% of patients that attended at least 5
of the group sessions have completed at least 1 MINT
session. Further, 42% of patients that attended no classes
have completed at least 1 MINT session, which suggest
that this intervention modality may be effective in certain
subgroups.
Despite the many challenges we have experienced to
date, implementation of this trial has presented us with
the unique opportunity to question which intervention
approaches work in real-world settings, where patients
have competing priorities and the demands of life often
outweigh the perceived benefits of participation. Based
on our experiences implementing the TLC-Clinic trial,
we would recommend future researchers conduct a for-
mative evaluation prior to implementing the trial at the
participating clinic sites.
A strength of formative evaluation is the involvement
of the target population, which can create buy-in and
limit potential barriers to acceptance among future par-
ticipants. This is accomplished by soliciting input and
acting on the suggestions from the pre-intervention
implementation phase to the completion of the project.
Formative evaluation can begin by surveying the physi-
cal space where participant recruitment and study visits
would occur and documenting clinic workflow processes
currently in place to determine how the study proce-
dures may complement rather than disrupt this process.
Semi-structured interviews and/or focus groups with
patients and physicians can also be utilized to elicit phy-
sicians’ attitudes about practice-based research, identify
patient barriers and facilitators to attending intervention
sessions, test the recruitment and data collection proce-
dures, and identify any organizational practices or struc-
tural barriers that may inhibit implementation of the
protocol as intended. A small, single arm study can also
be conducted to pilot the individual intervention com-
ponents and garner participant feedback on changes
that could be made to make the approach more effec-
tive. Finally, throughout the trial, observational notes by
study staff as well as short interviews with participants
can be completed to provide ongoing evaluation of the
acceptability of the intervention and fidelity to the pro-
tocol. This evaluation framework has shown to be suc-
cessful in other large multi-component behavioral
interventions [58,59].
In response to the implementation challenges we have
encountered to date, we recently incorporated patient
semi-structured interviews into the end of the group
classes to garner feedback about the structure and con-
tent of the classes, and suggestions for improvement.
Data collected from the exit interviews as well as the
research staff’s experiences will allow us to look inside
the ‘black box’ of the intervention design and delivery to
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patients to be the most beneficial so that future lifestyle
interventions in primary care practices can be tailored
to the needs of the population.
Trial Status
The TLC-Clinic trial began in February 2010 in the Belle-
vue Ambulatory Care Practice within Bellevue Hospital
Center (BHC). To date, we have recruited a total of 166
patients, of which 83 have been randomized to the MINT-
TLC arm. Patient recruitment will be completed in
approximately 2 months and patients will be followed for
6 months.
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